Facing death, returning to life: A qualitative analysis of MDMA-assisted therapy for anxiety associated with life-threatening illness
William Barone, Michiko Mitsunaga-Whitten, Lia Osunfunláyò Blaustein, Phillip Perl, Marisa Swank, Thomas Cody Swift
Frontiers in Psychiatry September 27, 2022 DOI: 10.3389/fpsyt.2022.944849 via DOAJ
Summary
AI-generated from the abstractAnxiety related to life-threatening illness is a common problem that current treatments only partially address. In a pilot clinical trial of MDMA-assisted therapy for this condition, participants described key therapeutic experiences: processing trauma and grief, having mystical and existential experiences, engaging more fully with the present moment with less physiological arousal, and facing fears about illness and death. Outcomes included better ability to cope with their illness, reduced psychological symptoms, improved vitality and quality of life, and greater emotional resilience even after medical relapse. The findings suggest that MDMA-assisted therapy may help people reconnect to life and build emotional resources for dealing with existential distress.
Study at a glance
| Characteristics | Qualitative study using interpretative phenomenological analysis Peer reviewed |
|---|---|
| Population | Adult participants from a pilot phase 2 clinical trial of MDMA-assisted therapy for anxiety associated with life-threatening illness |
| Interventions | 3 4-Methylenedioxymethamphetamine-Assisted Therapy |
| Duration | 3-month follow-up |
| Keywords | MDMA-Assisted Therapy Life-threatening illness Psycho-existential distress Existential anxiety Death and dying |
| Citations | 14 |
| Key finding | Participants reported that MDMA-assisted therapy helped them process trauma and grief, engage with existential fears, and develop greater emotional resilience and ability to cope with life-threatening illness. |
Abstract
Anxiety associated with life-threatening illness (LTI) is a pervasive mental health issue with a wide impact. A spectrum of traditional pharmacotherapies and psychotherapies are available, but offer varying success in reducing symptoms and improving quality of life. We explore a novel therapy for this condition by assessing prominent thematic elements from participant narrative accounts of a pilot phase 2 clinical trial of 3,4 Methylenedioxymethamphetamine-Assisted Therapy (MDMA-AT) for treating anxiety associated with LTI. Semi-structured qualitative interviews were conducted with a subset of adult participants 3 months following completion of this trial. This qualitative analysis sought to complement, clarify, and expand upon the quantitative findings obtained from the clinical trial to further understand the process and outcomes of the treatment. Interviews were coded and analyzed using an Interpretative Phenomenological Analysis (IPA) methodological framework. Participants described in detail their experiences from before, during and after the trial, which were analyzed and categorized into thematic clusters. Specifically, participants explored what they felt were important elements of the therapeutic process including processing trauma and grief, exploring mystical and existential experiences, engaging with the present moment with reduced physiological activation, and facing illness and existential fears. Outcomes of the treatment included increased ability to cope with LTI, reduced psychological symptoms, improved vitality and quality of life, and feeling more resourced. Participant narratives also showed a reconnection to life and greater emotional resilience in response to trauma and medical relapse. These findings are compared to similar treatments for the same indication. Limitations and challenges encountered in conducting this study are discussed along with implications for theory and clinical treatment.